Steven Michael Cohen Net Worth

The estimated Net Worth of Steven Michael Cohen is at least $72.6 Thousand dollars as of 4 August 2015. Steven Cohen owns over 5,000 units of vTv Therapeutics Inc stock worth over $72,550 and over the last 9 years Steven sold VTVT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Steven Cohen VTVT stock SEC Form 4 insiders trading

Steven has made over 2 trades of the vTv Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Steven bought 5,000 units of VTVT stock worth $75,000 on 4 August 2015.

The largest trade Steven's ever made was buying 5,000 units of vTv Therapeutics Inc stock on 4 August 2015 worth over $75,000. On average, Steven trades about 5,000 units every 0 days since 2015. As of 4 August 2015 Steven still owns at least 5,000 units of vTv Therapeutics Inc stock.

You can see the complete history of Steven Cohen stock trades at the bottom of the page.

What's Steven Cohen's mailing address?

Steven's mailing address filed with the SEC is C/O VTV THERAPEUTICS INC., 4170 MENDENHALL OAKS PKWY, HIGH POINT, NC, 27265.

Insiders trading at vTv Therapeutics Inc

Over the last 9 years, insiders at vTv Therapeutics Inc have traded over $100,050 worth of vTv Therapeutics Inc stock and bought 38,545,137 units worth $116,272,024 . The most active insiders traders include Ronald O Perelman, Srinivas Akkaraju, and Bros. Advisors Lp667, L.P.B.... On average, vTv Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $6,926,668. The most recent stock trade was executed by John A Fry on 28 November 2022, trading 61,000 units of VTVT stock currently worth $50,630.

What does vTv Therapeutics Inc do?

vtv therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. we have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.

Complete history of Steven Cohen stock trades at vTv Therapeutics Inc

vTv Therapeutics Inc executives and stock owners

vTv Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stephen Holcombe,
  President, Chief Executive Officer
• Rudy Howard,
  Chief Financial Officer, Executive Vice President
• Robin E. Abrams,
  Exec. Chairwoman of the Board
• Jeffrey Kindler,
  Chairman of the Board
• Noel Spiegel,
  Independent Director
• John Fry,
  Independent Director
• Howard Weiner,
  Independent Director
• Hersh Kozlov,
  Director
• Richard Nelson,
  Director
• Dr. Samuel B. Rollins Ph.D., J.D.,
  Sr. VP of Intellectual Property
• Dr. Robert C. Andrews Ph.D.,
  Sr. VP of Chemistry, Pharmaceutical Devel. and Quality
• Dr. Aaron H. Burstein,
  Sr. VP of Clinical Devel.
• Erin McDade,
  Chief of Staff
• David M. Lambert III,
  Sr. VP & Gen. Counsel
• Vanessa McDade,
  Chief Admin. Officer
• Dr. Carmen Valcarce Ph.D.,
  Chief Scientific Officer & Exec. VP
• Barry Brown,
  VP of Fin.
• Deepa Prasad,
  Pres, CEO & Director
• Daniel K Spiegelman,
  Director
• Paul G Savas,
  Director
• Steven Michael Cohen,
  Director
• Craig C Parker,
  Director
• Fahed Al Marzooqi,
  Director
• Larry Douglas Altstiel,
  Chief Medical Officer
• Srinivas Akkaraju,
  
• Jonathan Isaacsohn,
  Director
• Rich S. Nelson,
  Acting Chief Executive Officer
• Ronald O Perelman,
  10% owner
• Deepa Prasad,
  President and CEO
• Keith R. Harris,
  Director
• Steven L. Tuch,
  Chief Financial Officer
• Bros. Advisors Lp667, L.P.B...,
  
• Paul J Sekhri,
  President and CEO
• Anne M. Phillips,
  Director